Fair and adequate reimbursement for infectious diseases physicians is a key IDSA policy priority. The Society also advocates for access to appropriate treatments for patients with serious infections and for medical liability reform. 

Antibiotic development; strengthening U.S. antimicrobial resistance efforts, including surveillance, prevention and control, data collection and research; antimicrobial stewardship; antimicrobials in agriculture.

IDSA is committed to supporting improved diagnostics including providing recommendations to spur research and development of new tests, and encouraging their use in patient care and public health.

Influenza, other emerging infections, and bio-threats; U.S. preparedness and response, public health and research efforts, countermeasures (vaccines, drugs and diagnostics), non-therapeutic control measures. 

Funding for domestic and international ID programs, including antimicrobial resistance; immunization; drug, vaccine, and diagnostics development; and prevention and treatment of new and emerging infections.

IDSA prioritizes promoting sufficient U.S. investment in global infectious diseases responses and research, and in using the voices of physician scientists to inform multilateral and national global health policies. 

Supporting national immunization programs for children, adolescents, and adults, including health care workers; advancing research and development of new and improved vaccines.

Advancing biomedical and public health research priorities; supporting infrastructure that enables and strengthens ID research, clinical, and prevention efforts. 

Evidence-based practices and policies to prevent and control health care-associated infections (HAIs). 

As medical providers and scientists, you are the most trusted and credible advocate for federal health funding.

Developing and maintaining a workforce of ID clinicians, researchers, and public health experts.

MAP is for any IDSA or HIVMA member who is interested in advocacy